DUKE CLINICAL RESEARCH INSTITUTE
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1969-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.dcri.org
Clinical Trials
6
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
News
UNC Researcher Awarded $14.4 Million to Study Emerging Medications for Pediatric IBD
Michael D. Kappelman from UNC receives $14.4 million from PCORI to study new treatment options for pediatric inflammatory bowel diseases (PIBD).
Montelukast Fails to Improve COVID-19 Recovery in Outpatient Trial
A randomized, controlled trial found that montelukast, a common asthma drug, does not speed recovery from mild to moderate COVID-19 symptoms.
Montelukast Fails to Shorten COVID-19 Recovery Time in Outpatient Trial
• A randomized, controlled trial found that montelukast did not reduce the duration of COVID-19 symptoms in outpatients with mild to moderate illness. • The ACTIV-6 study involved 1,250 participants and assessed montelukast's effectiveness during the circulation of Omicron subvariants. • The median time to sustained recovery was 10 days in both the montelukast and placebo groups, indicating no significant benefit from the drug. • Researchers emphasize that knowing a treatment doesn't work is crucial to prevent unnecessary use and potential harm.